All In Biotech

Drug Trial Radar · NCT07317700

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

A Randomized, Open-label, Positive-controlled, Parallel-grouped, Multicenter Phase III Clinical Trial on the Efficacy and Safety of Flonoltinib Maleate Tablets in Patients With Intermediate- or High-risk Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Dec 30, 2027

Study completion Mar 30, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.

Conditions

  • MF

Interventions

  • Flonoltinib 75mgDrug

    Flonoltinib 75mg,qd

  • Ruxolitinib PhosphateDrug

    Ruxolitinib Phosphate ,control group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with >=35% reduction in spleen volume from baselineTime frame: Week 24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.